Non-Current Assets
Deferred Tax Assets
Bristol-Myers Squibb Deferred Tax Assets decreased by 3.8% to $5.18B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.5%, from $4.00B to $5.18B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 35.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ4 2019
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase may indicate past operating losses or tax credits that provide a future buffer, while a decrease suggests the utilization of these benefits to offset tax liabilities.
Detailed definition
This represents the future tax benefits that the company expects to realize due to temporary differences between the fin...
Peer comparison
Standard across all industries; levels depend heavily on the company's historical profitability and tax jurisdiction profile.
Metric ID:
non_current_assets_deferred_income_tax_assets_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $650.00M | $684.00M | $1.44B | $1.42B | $1.34B | $1.33B | $1.34B | $1.32B | $1.57B | $1.51B | $2.77B | $2.72B | $3.32B | $3.61B | $4.24B | $4.00B | $4.65B | $4.96B | $5.38B | $5.18B |
| QoQ Change | — | +5.2% | +110.4% | -1.5% | -5.7% | -0.6% | +1.1% | -2.0% | +19.4% | -3.7% | +82.8% | -1.6% | +22.0% | +8.6% | +17.4% | -5.6% | +16.3% | +6.8% | +8.4% | -3.8% |
| YoY Change | — | — | — | — | +105.7% | +94.3% | -6.6% | -7.1% | +17.6% | +13.9% | +106.0% | +106.8% | +111.4% | +138.4% | +53.0% | +46.8% | +39.8% | +37.5% | +27.0% | +29.5% |
Range$650.00M – $5.38B
CAGR+54.8%
Avg YoY Growth+57.1%
Median YoY Growth+43.3%
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's deferred tax assets?
- Bristol-Myers Squibb (BMY) reported deferred tax assets of $5.18B in Q1 2026.
- How has Bristol-Myers Squibb's deferred tax assets changed year-over-year?
- Bristol-Myers Squibb's deferred tax assets increased by 29.5% year-over-year, from $4.00B to $5.18B.
- What is the long-term trend for Bristol-Myers Squibb's deferred tax assets?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's deferred tax assets has grown at a 35.9% compound annual growth rate (CAGR), from $1.16B to $5.38B.
- What does deferred tax assets mean?
- Future tax savings the company expects to realize based on past financial activities.